BIOCELTIX S.A. ZY -10 (XI3) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.062x

Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) has a cash flow conversion efficiency ratio of -0.062x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.54 Million ≈ $-5.31 Million USD) by net assets (€73.28 Million ≈ $85.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

BIOCELTIX S.A. ZY -10 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how BIOCELTIX S.A. ZY -10's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does BIOCELTIX S.A. ZY -10 carry for a breakdown of total debt and financial obligations.

BIOCELTIX S.A. ZY -10 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BIOCELTIX S.A. ZY -10 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bundamedik Tbk PT JK:BMHS	0.083x
Miwon Holdings Co. Ltd KO:107590	0.012x
Michael Hill International Ltd AU:MHJ	-0.015x
MPH Health Care AG F:93M1	-0.004x
ADVENICA AB F:65R	0.098x
Q.BEYOND AG NA O.N. KONV. XETRA:QBY0	0.035x
Kino Indonesia Tbk PT JK:KINO	0.123x
Embellence Group AB ST:EMBELL	0.080x

Annual Cash Flow Conversion Efficiency for BIOCELTIX S.A. ZY -10 (2021–2025)

The table below shows the annual cash flow conversion efficiency of BIOCELTIX S.A. ZY -10 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see XI3 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€73.28 Million ≈ $85.67 Million	€-11.95 Million ≈ $-13.97 Million	-0.163x	+64.34%
2024-12-31	€38.42 Million ≈ $44.91 Million	€-17.57 Million ≈ $-20.54 Million	-0.457x	+67.55%
2023-12-31	€10.47 Million ≈ $12.24 Million	€-14.75 Million ≈ $-17.24 Million	-1.409x	+7.84%
2022-12-31	€5.15 Million ≈ $6.02 Million	€-7.87 Million ≈ $-9.21 Million	-1.529x	-128.26%
2021-12-31	€6.00 Million ≈ $7.01 Million	€-4.02 Million ≈ $-4.70 Million	-0.670x	--

About BIOCELTIX S.A. ZY -10

F:XI3 Germany Biotechnology

Market Cap

$105.68 Million

€90.40 Million EUR

Market Cap Rank

#19723 Global

#1815 in Germany

Share Price

€16.34

Change (1 day)

+0.49%

52-Week Range

€14.08 - €28.60

All Time High

€28.60